BIRMINGHAM, Ala.--(BUSINESS WIRE)--Jan 22, 2013--Atherotech Diagnostics Lab recently appointed cardiology expert and prolific researcher Peter A. McCullough, M.D., M.P.H., F.A.C.C., F.A.C.P., F.C.C.P., F.A.H.A., F.N.K.F., to its Medical Advisory Board.
With over 800 published, scientific communications, McCullough is an internationally recognized authority on the role of chronic kidney disease as a cardiovascular risk state. As a member of the Medical Advisory Board, he will counsel Atherotech in the expansion of its proprietary test portfolio and guide scientific research using the company’s patented VAP ® (Vertical Auto Profile) Lipid Panel. Atherotech’s Medical Advisory Board includes highly regarded physicians who bring expertise in current trends in cardiovascular disease identification, risk assessment and management, and research and outcome studies. To review individual, detailed biographies, please visit www.Atherotech.com/mad.
“Peter is a luminary in the field of cardiology and believes in the power of our VAP technology as the future of cardiovascular risk assessment,” CEO Michael Mullen said. “He is a welcome addition to our Medical Advisory Board, and we’re proud to partner with him.” McCullough’s cardiodiagnostic experience includes playing an integral role in developing the BNP (B-type natriuretic peptide) assessment, a blood test that helps clinicians evaluate complex cardiac functions. He is currently Chief Academic and Scientific Officer at St. John Providence Health System in Warren, Mich., where he oversees graduate medical education, corporate medical staff services, and research. McCullough is the current Chair of the National Kidney Foundation’s Kidney Early Evaluation Program, the nation’s largest community screening effort for chronic diseases. He is the co-editor of Reviews in Cardiovascular Medicine and serves on the editorial boards of multiple specialty journals. He has led numerous clinical trial steering, data safety monitoring, and events committees, and has testified before the U.S. Food and Drug Administration and the Congressional Oversight Panel.
For information on Atherotech Diagnostics Lab, visit www.Atherotech.com or call 877-901-8510. Health care professionals interested in real cases from the trenches of lipidology may visit www.CobblesCorner.com, Atherotech’s official blog. Atherotech is on Twitter at www.Twitter.com/Atherotech, on Facebook at www.Facebook.com/Atherotech, and broadcasting at www.YouTube.com/user/VAPatherotech.
About Atherotech Diagnostics Lab & the VAP Lipid Panel Atherotech Diagnostics Lab is a leading clinical reference laboratory specializing in cardiometabolic testing and disease management solutions. Atherotech’s proprietary and comprehensive VAP ® Lipid Panel enables clinicians to accurately stratify a patient’s cardiovascular risk and deliver personalized treatment strategies to improve health outcomes. The Vertical Auto Profile (VAP) technology reveals residual cardiometabolic risk as recommended in the NCEP ATP III, ADA/ACC Joint Consensus and AACE guidelines. The VAP Lipid Panel utilizes direct measurement to identify cholesterol, triglyceride and genetic lipid disorders. The company’s dedication to affordable, comprehensive disease management solutions includes Our Healthy Heart TM , a patient consultation program and expert lipid management education service to health care providers. For more information, please visit or call 1-866-VAP-TEST.CONTACT: Armada Medical Marketing Micki Sievwright, 651-228-1220 firstname.lastname@example.org KEYWORD: UNITED STATES NORTH AMERICA ALABAMA INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CARDIOLOGY HOSPITALS MEDICAL DEVICES RESEARCH SCIENCE SOURCE: Atherotech Diagnostics Lab Copyright Business Wire 2013 PUB: 01/22/2013 04:15 PM/DISC: 01/22/2013 04:15 PM http://www.businesswire.com/news/home/20130122006774/